Updated January 2, 2012
Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help BDSI.
November 29, 2011
The US Patent and Trademark Office has rejected all 191 claims made by New Jersey-based MonoSol Rx as unpatentable. The dispute centers on the technology that forms BDSI's drug delivery platform.
November 16, 2011
The company has $15.1 million in cash. But the Raleigh-based firm is working on two clinical-stage drug programs and it doesn't have enough money to pay for both of them.
Updated November 11, 2011
"We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.
September 29, 2011
The Raleigh-based company also says potential partners are still interested in the pain reliver.
September 29, 2011
The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.
August 24, 2011
The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.
October 20, 2010
The decision means $2.5 million in milestone payment for the Raleigh firm.
September 7, 2010
Benny Ward takes over as business and strategic development director at the drug delivery technology development firm.
May 10, 2010
The Raleigh-based firm can now sell its “breakthrough” pain killer drug outside of the U.S. It is seeking approval to sell Onsolis in Europe.
Updated April 20, 2010
The announced sale sends BDSI shares down 14 percent from Monday’s closing price of $4.21 per share.
September 2, 2009
Chief science officer is also leaving drug development firm, which recently won FDA approval for its first product.